Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter) Patent Expiration, LOE Window & CMS Spending

Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter) by GSK: FDA Orange Book core substance LOE 2027-12-18 (last listed 2031-04-11), 0 AB generics, $5.81B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN209482 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2027-12-18
Last Listed Patent or Exclusivity Date2031-04-11
Orange Book Patents (*PED Extensions)8 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.81B
2024 Medicare Part D Spend$5.29B
2024 Medicaid Spend$519.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.